Modelling the evolution of genetic instability during tumour progression

Center for Evolution and Cancer, University of California San Francisco San Francisco, CA, USA.
Evolutionary Applications (Impact Factor: 3.9). 02/2013; 6(1):20-33. DOI: 10.1111/eva.12024
Source: PubMed


The role of genetic instability in driving carcinogenesis remains controversial. Genetic instability should accelerate carcinogenesis by increasing the rate of advantageous driver mutations; however, genetic instability can also potentially retard tumour growth by increasing the rate of deleterious mutation. As such, it is unclear whether genetically unstable clones would tend to be more selectively advantageous than their genetically stable counterparts within a growing tumour. Here, we show the circumstances where genetic instability evolves during tumour progression towards cancer. We employ a Wright-Fisher type model that describes the evolution of tumour subclones. Clones can acquire both advantageous and deleterious mutations, and mutator mutations that increase a cell's intrinsic mutation rate. Within the model, cancers evolve with a mutator phenotype when driver mutations bestow only moderate increases in fitness: very strong or weak selection for driver mutations suppresses the evolution of a mutator phenotype. Genetic instability occurs secondarily to selectively advantageous driver mutations. Deleterious mutations have relatively little effect on the evolution of genetic instability unless selection for additional driver mutations is very weak or if deleterious mutations are very common. Our model provides a framework for studying the evolution of genetic instability in tumour progression. Our analysis highlights the central role of selection in shaping patterns of mutation in carcinogenesis.

Download full-text


Available from: Charles Swanton, Jul 22, 2014
  • Source
    • "In human disease, a synthetic lethality approach using poly ADP ribose polymerase (PARP) inhibitors in breast cancers with inherited defects in DNA repair is showing promise. The concern for such approaches is that tumour heterogeneity can also lead to faster tumour progression (Aktipis and Nesse, 2013) or even a surprising evolutionary viability of mutator phenotypes (Datta et al., 2013). It remains to be determined whether such an approach has a role in AML. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Acute myeloid leukaemia (AML) is an uncontrolled clonal proliferation of abnormal myeloid progenitor cells in the bone marrow and blood. Advances in cancer genomics have revealed the spectrum of somatic mutations that give rise to human AML and drawn our attention to its molecular evolution and clonal architecture. It is now evident that most AML genomes harbour small numbers of mutations, which are acquired in a stepwise manner. This characteristic, combined with our ability to identify mutations in individual leukaemic cells and our detailed understanding of normal human and murine haematopoiesis, makes AML an excellent model for understanding the principles of cancer evolution. Furthermore, a better understanding of how AML evolves can help us devise strategies to improve the therapy and prognosis of AML patients. Here, we draw from recent advances in genomics, clinical studies and experimental models to describe the current knowledge of the clonal evolution of AML and its implications for the biology and treatment of leukaemias and other cancers.
    Disease Models and Mechanisms 08/2014; 7(8):941-951. DOI:10.1242/dmm.015974 · 4.97 Impact Factor
  • Source
    • "Moreover, the difficulty to distinguish between drivers and passengers (Futreal, 2007; Frö hling et al., 2007) suggests that for a full understanding of cancer initiation it is insufficient to think of these two types of mutations only. So far, most models have focused on the idea that passenger mutations have no effect or only a little effect, whereas each driver mutation increases the fitness of the cell (Michor et al., 2004; Beerenwinkel et al., 2007; Bozic et al., 2010; Gerstung and Beerenwinkel, 2010; Antal and Krapivsky, 2011; Reiter et al., 2013; Durrett et al., 2010; Datta et al., 2013). Other models focus on the neutral accumulation of mutations (Durrett et al., 2009; Luebeck and Moolgavkar, 2002). "
    [Show abstract] [Hide abstract]
    ABSTRACT: We investigate the dynamics of cancer initiation in a model with one driver mutation and several passenger mutations. In contrast to previous models, the change in fitness induced by the driver mutation depends on the genetic background of the cell, in our case on the number of passenger mutations. The passenger mutations themselves have no or only a very small impact on the cell's fitness. This approach is motivated by the Burkitt Lymphoma, where the hallmark mutation, a translocation between the MYC gene and an immunoglobulin gene, alters the rate of apoptosis, but also the proliferation rate of cells. This way we obtain an epistatic fitness landscape, where the fitness of cells with the driver mutation is advantageous only if enough passenger genes have mutated. Otherwise the fitness might even be deleterious. Our analysis is based on an individual cell model in which the cells can divide or undergo apoptosis. In case of division the two daughter cells can mutate. This model shows a very interesting dynamical behavior. Since the driver mutation is deleterious on a background with only a few passenger mutations, there is a long period of stasis in the number of cells until a clone of cells has evolved with enough passenger mutations. Only when the driver mutation occurs in one of those cells, the cell population starts to grow exponentially.
    Journal of Theoretical Biology 10/2013; 358. DOI:10.1016/j.jtbi.2014.05.018 · 2.12 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Genomic instability is a characteristic of most cancers and it is argued that genomic instability is a driving force for tumorigenesis. Data herein demonstrate that genomic instability, as evidenced by microsatellite instability (MSI) and promoter methylation of DNA mismatch repair genes, is common in individual glands of pre-malignant colorectal lesions and raises interesting questions about the role of MSI in the development of colorectal carcinoma.Oncogene advance online publication, 11 February 2013; doi:10.1038/onc.2013.21.
    Oncogene 02/2013; 32(46). DOI:10.1038/onc.2013.21 · 8.46 Impact Factor
Show more